Cambrex Reports Third Quarter 2010 Results: Loss Per Share of $0.05

Cambrex Corporation

reports third quarter results for the period ended September 30, 2010. Highlights * Reported sales decreased by 14.6%, and excluding the impact of foreign currency, sales decreased 11.5% compared to third quarter 2009. * Adjusted EBITDA was $8.5 million in the third quarter 2010 compared to $11.0 million in the same quarter last year. * Debt, net of cash was $71.4 million at the end of third quarter 2010, a decrease of $5.5 million during the quarter including a positive $2.5 million impact of currency on foreign cash balances. * Acquired a 51% stake in Zenara Pharma, a Hyderabad, India based pharmaceutical company focused on the formulation of final dosage form products, for $20 million on November 2, 2010. * Narrowed the range of 2010 full year guidance for sales, excluding the impact of foreign currency, to a decline of between 3% and 5%, and Adjusted EBITDA to $41 to $44 million. Net Loss for the third quarter 2010 was $1.5 million or $0.05 per share compared to Net Income of $3.0 million or $0.10 per share in the third quarter 2009.